Previous Close | 2.0900 |
Open | 2.0800 |
Bid | 2.0100 x 400 |
Ask | 2.0800 x 900 |
Day's Range | 1.9900 - 2.0814 |
52 Week Range | 0.7710 - 28.6000 |
Volume | |
Avg. Volume | 10,794,552 |
Market Cap | 29.293M |
Beta (5Y Monthly) | 0.42 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -8.8600 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.32 |
MIAMI, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024 in New York City. Details for the Company’s presentation: Date:Tuesday, September 10, 2024 Time:5:00 – 5:30 p.m. ET The webcast for this c
Wa'el Hashad Wa'el Hashad, CEO, Longeveron Positive data from the Phase 2a clinical trial (CLEAR MIND ) evaluating Lomecel-B™ in Alzheimer’s disease presented in Featured Research Oral Presentation at Alzheimer’s Association International Conference® (AAIC)U.S. FDA granted Lomecel-B™ both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the treatment of mild Alzheimer’s diseasePhase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disea
MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report second quarter 2024 financial results and provide a business update on Wednesday, August 14, 2024 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call Detai